NasdaqGS:GILDBiotechs
AstraZeneca Pressure Puts Krystal Biotech, TG Therapeutics And Gilead Stocks In Focus
Healthcare investors are watching AstraZeneca closely after fresh comments about operating at Chinese speed, reaffirming a 2030 sales goal of $80b and reporting 6% revenue growth at constant exchange rates in the first half of 2026, even as the Wainua trial setback put its pipeline under scrutiny. This mix of confidence, competition from China and pressure to accelerate drug development could reshape how large pharmaceutical and biotechnology stocks are viewed. This article walks through 3...